Compare BNL & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNL | ACAD |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.9B |
| IPO Year | 2008 | 2000 |
| Metric | BNL | ACAD |
|---|---|---|
| Price | $19.74 | $21.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 22 |
| Target Price | $20.22 | ★ $30.55 |
| AVG Volume (30 Days) | ★ 3.5M | 1.7M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.87% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | 0.50 | ★ 2.30 |
| Revenue | $454,138,000.00 | ★ $726,437,000.00 |
| Revenue This Year | $7.99 | $18.90 |
| Revenue Next Year | $5.27 | $11.62 |
| P/E Ratio | $39.81 | ★ $9.45 |
| Revenue Growth | 5.17 | ★ 40.45 |
| 52 Week Low | $15.28 | $14.08 |
| 52 Week High | $19.91 | $28.35 |
| Indicator | BNL | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 62.30 | 41.70 |
| Support Level | $17.98 | $20.22 |
| Resistance Level | $19.82 | $22.03 |
| Average True Range (ATR) | 0.38 | 0.73 |
| MACD | 0.14 | 0.10 |
| Stochastic Oscillator | 90.88 | 26.88 |
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.